" class="no-js "lang="en-US"> Caresyntax Adds Industry Leaders to Advisory Board - Medtech Alert
Thursday, June 20, 2024

Caresyntax Adds Industry Leaders to Advisory Board

Caresyntax, the leading enterprise-level digital surgery platform delivering actionable insights to make surgery smarter and safer, announced today that Dan Wolterman, Vance Moore, and Scott Flora have joined the company’s advisory board. The new members will use their expertise to help optimize Caresyntax’s platform for those who use real-world evidence to support surgical teams, including medical device companies.

“As hospitals begin their climb out of a significant surgical backlog due to the pandemic, there will continue to be a critical need for high-value medical technology in operating rooms,” said Dennis Kogan, Caresyntax founder and CEO. “These leaders join the Caresyntax advisory board with invaluable experience in health care, medical device technology, and virtual care. We are grateful for the insights they will provide as we continue to advance our platform.”

Wolterman previously served as president and CEO of Memorial Hermann Health System in Houston, the largest not-for-profit health system in Southeast Texas. He is also a member of the board of Vizient, the largest member-owned health care company in the United States with over 4,000 not-for-profit health system/hospital members. He currently serves on the boards of NuVasive, Inc., BactoByte, Inc., and Legacy ER/Urgent Care, where he is a strong advocate for patient safety and quality measures.

Moore is a board member of Omnicell Incorporated (NASDAQ: OMCL), and has held operational and sales roles in health care consulting, distribution, manufacturing, third-party logistics, and provider operations. He formerly was president of business integration for Mercy Virtual, the telehealth and technology support branch of Mercy Health. He also sits on the governing council of National Evaluation System for Health Technology (NESTcc), a collaboration with medical device stakeholders to more efficiently generate better evidence for medical device evaluation and regulatory decision making. Additionally, he was president and CEO of ROi, and worked with Baxter/Allegiance, Cardinal Health, and the health care division of the UPS Logistics Group.

Flora brings insights gained from more than 40 years of health care leadership experience in surgical devices. He currently serves as Board Chair for Palliare Ltd and New View Surgical, and is an independent director on the Board of Cytoveris. He previously served as interim president and CEO of Invuity Inc. which was acquired by Stryker; interim CEO of Conventus Orthopaedics; president and CEO of OmniGuide Surgical; president of Covidien’s Surgical Device Group; and president of Smith+Nephew Orthopedic Reconstruction. Recently, Flora served as the Chair of Conventus/Flower Orthopaedics and has prior experience on three public company boards, Invuity, MAKO Surgical, and Tengion.

This announcement comes as Caresyntax recently closed a $100 million Series C funding round led by PFM Health Sciences LP. The company was also recently selected by American Board of Surgery for a pilot program to enhance certification with video-based assessments. The new advisory board members will help Caresyntax build on its momentum to accelerate expansion in key markets, continue research and development of its AI analytics, and further build out its platforms.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more